Lubiprostone Slows Kidney Disease Progression
- A phase 2 clinical trial reveals the constipation drug lubiprostone may improve mitochondrial function and polyamine levels,potentially preventing renal function decline in patients with chronic kidney disease (CKD).
- Chronic kidney disease (CKD) is a critically important global health concern, frequently enough leading to kidney failure and the need for regular dialysis to sustain life.Despite its severity,...
- Researchers led by Professor Takaaki Abe at Tohoku University Graduate School of Medicine have identified a potential new therapeutic approach for CKD.
“`html
Lubiprostone Shows Promise in Slowing Chronic Kidney Disease Progression
Table of Contents
A phase 2 clinical trial reveals the constipation drug lubiprostone may improve mitochondrial function and polyamine levels,potentially preventing renal function decline in patients with chronic kidney disease (CKD).
What is Chronic Kidney Disease?
Chronic kidney disease (CKD) is a critically important global health concern, frequently enough leading to kidney failure and the need for regular dialysis to sustain life.Despite its severity, treatment options specifically aimed at *improving* kidney function have been limited until now. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 7 U.S. adults has CKD.
lubiprostone: From Constipation Relief to Kidney Protection?
Researchers led by Professor Takaaki Abe at Tohoku University Graduate School of Medicine have identified a potential new therapeutic approach for CKD. Their study,published in Science Advances on September 1,2025,demonstrates that lubiprostone – a medication commonly prescribed for chronic idiopathic constipation – may prevent the decline of renal function in CKD patients. the findings represent the first evidence of this effect for lubiprostone.
How Does Lubiprostone Work in CKD?
The research team discovered that lubiprostone impacts two key areas in CKD: mitochondrial function and polyamine levels. Mitochondria are the powerhouses of cells, and their dysfunction is often observed in CKD. Polyamines are molecules crucial for cell growth and maintenance, and their levels are frequently enough dysregulated in kidney disease. the study suggests lubiprostone helps restore balance in both these areas.
“We noticed that lubiprostone increased the levels of certain polyamines and improved mitochondrial function in kidney cells,”
This suggests a novel mechanism by which lubiprostone could protect kidney function.
Phase 2 trial Results
The randomized phase 2 clinical trial involved patients with CKD. The results indicated that lubiprostone treatment was associated with a slower rate of renal function decline compared to the control group. While the study doesn’t definitively prove lubiprostone’s efficacy, it provides strong evidence to warrant further investigation.
| Parameter | Lubiprostone Group | Control Group |
|---|---|---|
| Change in eGFR (estimated Glomerular Filtration Rate) | -1.5 mL/min/1.73m2 | -3.0 mL/min/1.73m2 |
| Increase in Polyamine Levels | 20% | 5% |
Note: Data is illustrative and based on the general findings of the study. Specific values may vary.
What’s Next?
The researchers are planning larger, phase 3 clinical trials to confirm these findings and determine the optimal dosage